4.11
Cytosorbents Corp stock is traded at $4.11, with a volume of 658.30K.
It is up +34.31% in the last 24 hours and down -28.27% over the past month.
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
See More
Previous Close:
$3.06
Open:
$3.01
24h Volume:
658.30K
Relative Volume:
8.65
Market Cap:
$12.95M
Revenue:
$37.20M
Net Income/Loss:
$-11.85M
P/E Ratio:
-21.54
EPS:
-0.1908
Net Cash Flow:
$-10.59M
1W Performance:
+8.44%
1M Performance:
-28.27%
6M Performance:
-66.31%
1Y Performance:
-77.31%
Cytosorbents Corp Stock (CTSO) Company Profile
Name
Cytosorbents Corp
Sector
Industry
Phone
973-329-8885
Address
305 COLLEGE ROAD EAST, PRINCETON, NJ
Compare CTSO vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
CTSO
Cytosorbents Corp
|
4.11 | 12.95M | 37.20M | -11.85M | -10.59M | -0.1908 |
|
ABT
Abbott Laboratories
|
104.89 | 181.50B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
MDT
Medtronic Plc
|
94.75 | 121.20B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
SYK
Stryker Corp
|
294.66 | 113.02B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
BSX
Boston Scientific Corp
|
44.39 | 64.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
86.60 | 49.92B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-07-23 | Initiated | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-17-20 | Initiated | Jefferies | Buy |
| Sep-01-20 | Initiated | SVB Leerink | Outperform |
| Aug-08-17 | Reiterated | Maxim Group | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| May-24-16 | Initiated | Maxim Group | Buy |
| Oct-29-15 | Upgrade | WBB Securities | Speculative Buy → Buy |
| May-12-15 | Reiterated | MLV & Co | Buy |
| Apr-01-15 | Reiterated | MLV & Co | Buy |
| Mar-05-15 | Initiated | MLV & Co | Buy |
| Feb-25-15 | Initiated | WBB Securities | Speculative Buy |
| Jan-27-15 | Reiterated | H.C. Wainwright | Buy |
View All
Cytosorbents Corp Stock (CTSO) Latest News
Cytosorbents Corporation (CTSO) Stock Price, News, Quote & History - Yahoo! Finance Canada
CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care - prnewswire.com
Cytosorbents Corporation (CTSO) stock price, news, quote and history - uk.finance.yahoo.com
Cytosorbents Corporation (CTSO) stock price, news, quote and history - Yahoo Finance Singapore
CytoSorbents regains Nasdaq $1.00 minimum bid compliance; MVLS shortfall remains under review - TradingView
Nasdaq keeps CytoSorbents (NASDAQ: CTSO) on watch after $1 bid price return - Stock Titan
CytoSorbents regains Nasdaq minimum bid price compliance - Investing.com
CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement - PR Newswire
CytoSorbents Regains Compliance With Nasdaq Minimum Bid Price Requirement - Moomoo
Cytosorbents Corp (CTSO) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Cytosorbents Corp (CTSO) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
Cytosorbents Corp (CTSO) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Cytosorbents Corp (HQE) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Cytosorbents Corp (HQE) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
CEO Phillip Chan Buys 3,774 Shares of CytoSorbents Corp (CTSO) - GuruFocus
Cytosorbents CEO Phillip Chan buys $22,644 in common stock - Investing.com
Cytosorbents (CTSO) CEO adds to stake in open-market buy - Stock Titan
Cytosorbents president & COO Vincent Capponi buys $12,536 in stock By Investing.com - Investing.com India
Cytosorbents president & COO Vincent Capponi buys $12,536 in stock - Investing.com
Cytosorbents (CTSO) director buys shares in open-market trades without a preset plan - Stock Titan
Cytosorbents (CTSO) COO adds shares in open‑market buy - Stock Titan
CytoSorbents at H.C. Wainwright conference: breakeven, drug hopes - Investing.com
CytoSorbents Corp (STU:HQE) Stock Price & 30 Year Financial Data - GuruFocus
CytoSorbents to present at H.C. Wainwright conf... - Pluang
CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Morningstar
Cytosorbents CEO Phillip Chan buys 200,000 shares for $70,000 - Investing.com India
Cytosorbents CEO Phillip Chan buys 200,000 shares for $70,000 By Investing.com - Investing.com South Africa
Cytosorbents CEO Phillip Chan buys 200,000 shares for $70,000 By Investing.com - Investing.com Nigeria
Cytosorbents CEO Phillip Chan buys 200,000 shares for $70,000 - Investing.com
Cytosorbents CEO Phillip Chan buys 200,000 shares for $70,000 By Investing.com - Investing.com Canada
Cytosorbents Corp (CTSO) CEO bought more shares in the open market, adding to his stake - Stock Titan
CytoSorbents Corp (STU:HQE) Stock Earnings Transcripts - GuruFocus
CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights - easternprogress.com
CytoSorbents to present at Moody Capital Soluti... - Pluang
CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference - The Globe and Mail
CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference - TradingView
CytoSorbents Plans 1-for-20 Reverse Stock Split to Maintain Nasdaq Listing - citybiz
CytoSorbents to implement 1-for-20 reverse stoc... - Pluang
CytoSorbents Announces Reverse Stock Split - Morningstar
CytoSorbents Announces Reverse Stock Split - Yahoo Finance
CytoSorbents Announces Reverse Stock Split - PR Newswire
CTSO Looks 61.4% Undervalued on GF Value™ Amid Challenging Funda - GuruFocus
CytoSorb reduces severe bleeding by 37% in urge... - pluang.com
CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings - Yahoo Finance
A blood-cleansing device was linked to 37% less severe bleeding in urgent heart surgery - Stock Titan
Cytosorbents Earnings Call Balances Progress and Risk - The Globe and Mail
Cytosorbents Earnings Call Balances Progress and Risk - TipRanks
Cytosorbents (CTSO) Financial Update: EPS Comes in Below Forecast; Market Follow-Through: Shares Finish 4.56% LowerEarnings Season Outlook - vinanet.vn
CTSO: CytoSorbents Future Value Drivers Support Price Target of $4.00 - Yahoo Finance
Cytosorbents Corp Stock (CTSO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytosorbents Corp Stock (CTSO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sobel Alan D. | Director |
Sep 15 '26 |
Buy |
6.10 |
2,500 |
15,254 |
9,887 |
| Capponi Vincent | President and COO |
Sep 14 '26 |
Buy |
6.05 |
2,073 |
12,537 |
40,387 |
| Chan Phillip P. | Chief Executive Officer |
Sep 04 '26 |
Buy |
0.35 |
200,000 |
70,000 |
1,944,432 |
| MARIANI PETER J | Chief Financial Officer |
Jun 15 '26 |
Buy |
0.44 |
100,000 |
44,000 |
638,113 |
| Chan Phillip P. | Chief Executive Officer |
Jun 15 '26 |
Buy |
0.43 |
10,333 |
4,443 |
1,744,432 |
| Chan Phillip P. | Chief Executive Officer |
Jun 12 '26 |
Buy |
0.40 |
251,136 |
100,454 |
1,734,099 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):